Wockhardt announces approval of Cefuroxime Axetil Tablets , August 2 , 2005, Mumbai

Pharmaceutical and biotechnology major Wockhardt Limited has received approval from the United States Food & Drug Administration (US FDA) for marketing Cefuroxime Axetil in the US market. Wockhardt’s US subsidiary, Wockhardt USA is expected to launch the broad-spectrum cephalosporin antibiotic tablets in three strengths - 125 mg, 250 mg and 500 mg - over the next few weeks. As per IMS data, the current market for Cefuroxime Axetil in the US is estimated to be around US $ 58 million.

Wockhardt USA is wholly owned subsidiary of Wockhardt Ltd, a leading research-based pharmaceutical and health care Indian company headquartered in India. Through its sales and marketing headquarters in New Jersey, Wockhardt USA is committed to providing safe and affordable generic medicines to its US customers. For information on Wockhardt Group, please visit www.wockhardt.com

Important Disclaimer
The information provided in this website is for general and/or educational purpose only and is not intended to replace consultation with a qualified health care professional. For information on a specific medicine or for answers to your own particular health concerns, you should always consult with your doctor or pharmacist for their professional advice. Wockhardt USA accepts no liability for any damages, including without limitation, direct, indirect, incidental, consequential or punitive damages, arising out of or due to information given or not given in this website. Use of any information contained in this website is subject to your acceptance of Term of Use Agreement and/or our Privacy Policy Statement

For further information, please contact:
Wockhardt USA, Inc.
75 Ronald Reagan Blvd.
Warwick, NY 10990
Phone: (845) 987-1191
Fax: (845) 987-1193
Email: usa@wockhardt.com